Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs Investigator's Choice in HER2+ Gastric/GEJ Cancer
NCT06123494Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab rezetecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Hengrui. Primary endpoint: Overall Survival at 42 months. Started Jan 2024; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06123494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06123494.